Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Yuhei, Harutani"'
Autor:
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 402-409 (2024)
Abstract Background As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertin
Externí odkaz:
https://doaj.org/article/bf9f4e65fe294138b6c32c0d9d62d1af
Autor:
Eriko Murakami, Hiroaki Akamatsu, Shunsuke Teraoka, Toshiaki Takakura, Eri Takase, Masanori Tanaka, Takahiro Kaki, Yuhei Harutani, Katsuyuki Furuta, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Yuichi Ozawa, Masanori Nakanishi, Yasuhiro Koh, Toshio Shimokawa, Nobuyuki Yamamoto
Publikováno v:
Cancer Medicine, Vol 13, Iss 4, Pp n/a-n/a (2024)
Abstract Background Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)‐based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires cla
Externí odkaz:
https://doaj.org/article/936934c8acbe4ec093a80de605ccb236
Autor:
Nobuyuki Yamamoto, Yuichi Ozawa, Takeya Sugimoto, Yuichiro Azuma, Yuhei Harutani, Takanori Yoshikawa, Kuninobu Kanai
Publikováno v:
BMJ Open, Vol 10, Iss 7 (2020)
Introduction Triplet regimen of carboplatin or cisplatin with pemetrexed and pembrolizumab is a standard treatment for patients with advanced, chemo-naïve, non-squamous non-small cell lung cancer. However, subgroup analysis for patients aged ≥75 y
Externí odkaz:
https://doaj.org/article/9c2038878ed14ed7b537c26e00ac1389
Autor:
Siew-Kee, Low, Ryo, Ariyasu, Ken, Uchibori, Rie, Hayashi, Hiu Ting, Chan, Yoon Ming, Chin, Takahiro, Akita, Yuhei, Harutani, Ayu, Kiritani, Ryosuke, Tsugitomi, Ryo, Manabe, Shinsuke, Ogusu, Yoshiaki, Amino, Satoru, Kitazono, Noriko, Yanagitani, Yusuke, Nakamura, Makoto, Nishio
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Genomic profiling of tumors from cancer patients facilitates molecular-guided therapy. The turnaround time is one of important issues to deliver results timely for clinical decisions. The Ion Torrent™ Genexus™ Integrated Sequencer aut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6714c5cce1454eef30da0abcb17473de
https://doi.org/10.21037/tlcr-21-981
https://doi.org/10.21037/tlcr-21-981
Autor:
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Annals of Oncology. 33:S510-S511
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52b1940dc7694563f5d78b38b8be204f
https://doi.org/10.1016/j.annonc.2022.05.215
https://doi.org/10.1016/j.annonc.2022.05.215
Autor:
Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Kazushige Wakuda, Yuki Sato, Yoshitaka Kawa, Toshihide Yokoyama, Motohiro Tamiya, Ryota Hiraoka, Naoki Shingu, Hideki Ikeda, Akihiro Tamiya, Masaki Kanazu, Eisaku Miyauchi, Satoru Miura, Masaaki Yanai, Makiko Yomota, Ryotaro Morinaga, Takashi Yokoi, Akito Hata, Hidekazu Suzuki, Hirotaka Matsumoto, Shinya Sakata, Naoki Furuya, Yuhei Harutani, Ichiro Nakachi, Ayumu Otsuki, Shinya Uematsu, Satoshi Hara, Keiki Yokoo, Takeya Sugimoto, Nobuyuki Yamamoto
Publikováno v:
European journal of cancer (Oxford, England : 1990). 166
This study aimed to determine the incidence and clinical course of epidermal growth factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT).We conducted a multicentre, retrospective, cohort study of patients with advanced EGFR-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bb488f941faf1e952084b5ab48fa632
https://pubmed.ncbi.nlm.nih.gov/35278824
https://pubmed.ncbi.nlm.nih.gov/35278824
Autor:
Nahomi Tokudome, Nobuyuki Yamamoto, Eri Takase, Atsushi Hayata, Eriko Murakami, Yuichi Ozawa, Masanori Tanaka, Ryota Shibaki, Shunsuke Teraoka, Takeya Sugimoto, Takahiro Kaki, Nao Yamagata, Jun Oyanagi, Yasuhiro Koh, Katsuyuki Furuta, Hiroaki Akamatsu, Keita Mori, Yuhei Harutani, Yuka Okuda
Publikováno v:
The Oncologist
Background Although predictive value of immune‐related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) have been suggested by several studies, their assessments were insufficient because patients were categorized only by the o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7352b560f7a3ac0bcb3cbba9bd7b6739
https://doi.org/10.1634/theoncologist.2019-0299
https://doi.org/10.1634/theoncologist.2019-0299
Autor:
Motohiro Tamiya, Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Akito Hata, Hirotaka Matsumoto, Atsushi Nakamura, Yuko Oya, Hisanori Amimoto, Haruko Daga, Hideki Ikeda, Shinya Sakata, Hidekazu Suzuki, Satoshi Ikeda, Yuhei Harutani, Ryota Hiraoka, Masaaki Yanai, Yoichiro Hamamoto, Nobuyuki Yamamoto
Publikováno v:
Journal of Clinical Oncology. 40:8567-8567
8567 Background: Chemo-immunotherapy is the standard 1st-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). Prospective data about underrepresented populations outside the clinical trial such as elderly or poor risk has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d91d69b9b9a64fad75e5b7925649f0d
https://doi.org/10.1200/jco.2022.40.16_suppl.8567
https://doi.org/10.1200/jco.2022.40.16_suppl.8567
Autor:
Yuhei Harutani, Yuichi Ozawa, Eriko Murakami, Koichi Sato, Jun Oyanagi, Hiroaki Akamatsu, Takanori Yoshikawa, Ryota Shibaki, Takeya Sugimoto, Katsuyuki Furuta, Shunsuke Teraoka, Nahomi Tokudome, Atsushi Hayata, Hiroki Ueda, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto
Publikováno v:
Cancer immunology, immunotherapy : CII. 71(9)
While PD-1/L1 inhibitors are characterized by durable tumor control, they also prolong survival without prolongation of progression-free survival (PFS) in part of patients. However, little is known about the factors and mechanisms involved in this. B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4408f16c1a3de647fb466744ec400833
https://pubmed.ncbi.nlm.nih.gov/35037070
https://pubmed.ncbi.nlm.nih.gov/35037070
Autor:
Nahomi Tokudome, Shunsuke Teraoka, Ryota Shibaki, Eriko Murakami, Jun Oyanagi, Masanori Nakanishi, Yuhei Harutani, Nobuyuki Yamamoto, Toshiaki Takakura, Yuka Okuda, Takeya Sugimoto, Kouichi Sato, Masanori Tanaka, Yuichi Ozawa, Atsushi Hayata, Yuka Kitamura, Hiroaki Akamatsu, Yasuhiro Koh, Katsuyuki Furuta, Hiroki Ueda, Junya Fukuoka
Publikováno v:
Cancer Science
CD24, a heavily glycosylated glycosylphosphatidylinositol–anchored surface protein, inhibits phagocytosis as potently as CD47. The relationship between such anti‐phagocytic factors and the immune response with immune–checkpoint inhibitors (ICI)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc26129824c4689c6cb7258a8dc1b4b8
https://pubmed.ncbi.nlm.nih.gov/33084148
https://pubmed.ncbi.nlm.nih.gov/33084148